EyePoint Pharmaceuticals

Press Releases

pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2015 Results
Sep 09, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its fourth quarter and fiscal year ended June 30, 2015
pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation's BioInterface 2015 Annual Symposium
Sep 03, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr. Paul Ashton , president and CEO of pSivida Corp. , will speak at the BioInterface 2015 Annual Symposium
pSivida Corp Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information
Sep 02, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2015 will be released after the market
pSivida CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend
Jul 21, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr. Paul Ashton , president and CEO of pSivida Corp. , will speak at a special workshop focusing on ocular
pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis
Jul 13, 2015
Statistically Significant Reduction in Recurrence of Disease and Statistically Significant Improvement in Visual Acuity WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases,
pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next Week
Jul 07, 2015
Dr. Glenn J. Jaffe to Present at 33 rd Annual Scientific Meeting of American Society of Retina Specialists WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, announced that
pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015
Jun 24, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr. Paul Ashton , president and CEO of pSivida Corp. , will present at the International Symposium on Ocular
pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis
May 19, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV); (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced positive safety data from its ongoing assessment of masked safety data from its first Phase III clinical
pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company
May 12, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treating eye diseases, today announced that it has signed two funded technology evaluation agreements with a leading global pharmaceutical company.
pSivida Corp. Reports Third Quarter FY 2015 Results
May 08, 2015
Clear FDA Regulatory Path for Medidur ™ for Posterior Uveitis NDA Filing Planned in First Half of 2017 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced
pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information
May 01, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2015 will be released before the market open
pSivida Corp. Reports ILUVIEN® for DME Approved in Poland
Apr 14, 2015
Marks 17 th European Approval WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Office for Registration of Medicinal Products , Medical Devices and
pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur™ for Posterior Uveitis
Mar 26, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the completion of the originally targeted enrollment of 120 patients in its pivotal Phase III clinical trial
pSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23
Feb 17, 2015
Live Launch Webinar on March 2 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that initial nationwide shipments of ILUVIEN® for diabetic macular edema
pSivida Corp. Reports Second Quarter FY 2015 Results
Feb 05, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2014 .
pSivida CEO to Present at 17Th Annual BioCEO & Investor Conference February 9
Feb 03, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 17 th Annual BioCEO & Investor Conference ,
pSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information
Jan 30, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2015 will be released after the market
pSivida Reports ILUVIEN® Receives Marketing Authorization in Two More EU Countries
Jan 26, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Finland and Luxembourg have granted marketing authorization to ILUVIEN® for the treatment of vision
pSivida Reports Commencement of ILUVIEN® Sales in Portugal
Jan 14, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the sale of ILUVIEN® for diabetic macular edema (DME) has begun in Portugal .
pSivida Reports ILUVIEN® Granted Marketing Authorization in the Netherlands
Dec 01, 2014
Now Approved in 14 Countries Worldwide WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Dutch Inspectie voor de Gezondheidszorg (IGZ) has granted
Displaying 101 - 120 of 327
EyePoint Pharmaceuticals